SecBot SecBot
Biotech Drug Report Generated Jul 2, 2026

zoldonrasib

RVMD·Revolution Medicines, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
At least 2-3 years assuming successful Phase 3 readout and regulatory filing; could be accelerated if FDA allows filing based on Phase 1 data under Breakthrough Therapy Designation, but no such filing has been announced.
Why 4/10
Zoldonrasib's Phase 3 RASolute 305 trial (1L metastatic PDAC) began enrolling in June 2026; a primary readout is likely 2-3 years away. No PDUFA date or accelerated filing announced despite Breakthrough Therapy Designation. The next hard binary catalyst is >12 months out, capping the score at 5. Recent Phase 1/2 data presentations (AACR Apr 2026, ESMO GI Jul 2026) have already been absorbed by the market.
Actionable Insight NEUTRAL

Zoldonrasib is a promising next-gen KRAS G12D inhibitor with impressive Phase 1 data, but the next hard catalyst (Phase 3 readout) is years away. The stock RVMD trades near ~$187 with a consensus price target of ~$193, much of the near-term value already reflects strong daraxonrasib (RMC-6236) Phase 3 data in pancreatic cancer. Watch for regulatory filing updates given Breakthrough Therapy Designation, and enrollment updates for RASolute 305 and 309 trials. Short interest at ~6.25% of float with 4.3 days to cover adds optionality.

Price Chart

Loading chart...

Executive Summary

Zoldonrasib is Revolution Medicines' investigational oral RAS(ON) G12D-selective covalent inhibitor for KRAS G12D-mutant cancers, a mutation for which no approved targeted therapy exists. The FDA granted Breakthrough Therapy Designation in January 2026 for previously treated KRAS G12D NSCLC based on Phase 1 data showing a 52% objective response rate, 93% disease control rate, and 11.1-month median progression-free survival. The drug is now entering Phase 3 development: the RASolute 305 trial (1L metastatic pancreatic cancer) began dosing in June 2026. Recent Phase 1/2 combo data at ESMO GI 2026 showed zoldonrasib + chemotherapy achieved up to 82% ORR in first-line PDAC. While early clinical data is compelling, the stock's recent 139% six-month rally partially reflects these catalysts, and the next binary Phase 3 readout is years away.

How It Works

Zoldonrasib is an oral targeted cancer therapy designed to attack a specific mutant form of the RAS protein called KRAS G12D, a common cancer driver found in pancreatic, lung, and colorectal cancers. It works by binding to the "active" (ON) form of the mutant protein and blocking its cancer-driving signals. It forms a tri-complex with a cellular protein (cyclophilin A) to lock the mutant RAS in an inactive state. Think of it as a key that only fits a specific broken lock (G12D mutation) found inside cancer cells.

Trial Status

Phase 3 RASolute 305 trial (NCT07621718) began treating patients in June 2026, a global, randomized, double-blind, placebo-controlled study evaluating zoldonrasib + chemo vs placebo + chemo in first-line metastatic KRAS G12D pancreatic cancer. Phase 1 monotherapy data in previously treated KRAS G12D NSCLC presented at AACR 2026 showed 52% ORR, 93% DCR, 11.1 months median PFS. Phase 1/2 combo data presented at ESMO GI July 2026 showed zoldonrasib + chemo ORR up to 82% in 1L PDAC and zoldonrasib + daraxonrasib ORR 47-50% in pretreated PDAC. A separate Phase 1/1b study (NCT06040541) in KRAS G12D solid tumors is ongoing.

The Two-Sided Case

▲ Bull Case6
First-in-class KRAS G12D targeted therapy, no approved drugs exist for this mutation, representing a large unmet need in pancreatic (~50% KRAS G12D), lung (~4% KRAS G12D), and colorectal cancers.
Phase 1 monotherapy data in NSCLC is striking: 52% ORR, 93% DCR, 11.1mo median PFS, and 73% 12-month OS (AACR 2026), comparable to approved KRAS G12C inhibitors in their indication.
ESMO GI 2026 combo data showed 82% ORR for zoldonrasib + chemo in 1L PDAC and 47-50% ORR for zoldonrasib + daraxonrasib in pretreated PDAC, supporting a broad label expansion strategy.
FDA granted Breakthrough Therapy Designation (Jan 2026), first ever for a KRAS G12D-targeted drug, allowing expedited development and potential rolling review.
Massive institutional support: BlackRock added 25.6% in Q1 2026, and top holders include Vanguard, Farallon Capital (held $1.3B+), Baker Bros. ($929M), and FMR LLC ($823M).
Part of a broader RAS(ON) platform at Revolution Medicines, synergies with daraxonrasib (multi-selective RAS inhibitor) could create a franchise in pancreatic cancer.
▼ Bear Case7
Phase 3 RASolute 305 trial just began enrolling (June 2026); readout is likely 2-3+ years away with no near-term binary catalyst to drive share price.
Competition is emerging: Mirati/BMS' MRTX1133 (G12D inhibitor) and Amgen's AMG 193 are in earlier-stage development for the same target.
The stock has already rallied ~139% over 6 months and ~258% over 12 months, much of the zoldonrasib optimism may already be priced in at ~$187 with a consensus PT of ~$193 (limited 3% upside).
EPS estimates are being revised down: 2026 EPS estimates fell from -$7.48 to -$8.05 (16 downward revisions in 30 days), indicating rising R&D spend.
Some notable institutional exits in Q1 2026: Norges Bank (exit), Point72 (exit), and significant trims from Balyasny (-94%), Allianz (-87%), and Pictet (-51%).
Pancreatic cancer is a notoriously difficult indication, the RASolute 302 trial for daraxonrasib in 2L PDAC showed positive results, but reading through to 1L PDAC with chemo combinations carries safety/efficacy risk.
Non-dilutive insider selling: Director Sushil Patel sold shares under a 10b5-1 plan at ~$183-192 in late June 2026.

Upcoming Catalysts

  • Enrollment updates for RASolute 305 Phase 3 trial (1L metastatic PDAC)
  • Potential regulatory filing strategy announcement given Breakthrough Therapy Designation
  • Additional Phase 1/2 combo data at future medical conferences (ASCO, ESMO, AACR)
  • Phase 3 RASolute 303 trial-in-progress updates for daraxonrasib (correlated pipeline value)
  • Quarterly earnings reports with pipeline and regulatory updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Revolution Medicines, Inc. Press Release RVMD ·Originating report

Sources · 14

Hover a chip for the title
1 ir.revmed.com2 aacrjournals.org3 biospace.com4 ir.revmed.com5 markets.businessinsider.com6 ir.revmed.com7 onclive.com8 clinicaltrials.gov9 clinicaltrials.gov10 marketbeat.com11 stocktitan.net12 biospace.com13 targetedonc.com14 ir.revmed.com